Top-Rated Stocks NASDAQ:NTLA Intellia Therapeutics - NTLA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $37.56 +1.54 (+4.28%) (As of 03/29/2023 12:00 AM ET) Add Compare Share Share Today's Range$36.18▼$37.7250-Day Range$33.30▼$44.8252-Week Range$32.44▼$78.58Volume736,554 shsAverage Volume1.17 million shsMarket Capitalization$3.31 billionP/E RatioN/ADividend YieldN/APrice Target$87.18 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Intellia Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside132.1% Upside$87.18 Price TargetShort InterestBearish8.95% of Shares Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.69Based on 11 Articles This WeekInsider TradingSelling Shares$431,934 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($5.81) to ($5.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.50 out of 5 starsMedical Sector155th out of 999 stocksDiagnostic Substances Industry3rd out of 14 stocks 4.4 Analyst's Opinion Consensus RatingIntellia Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 15 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $87.18, Intellia Therapeutics has a forecasted upside of 132.1% from its current price of $37.56.Amount of Analyst CoverageIntellia Therapeutics has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.95% of the outstanding shares of Intellia Therapeutics have been sold short.Short Interest Ratio / Days to CoverIntellia Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Intellia Therapeutics has recently decreased by 2.72%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldIntellia Therapeutics does not currently pay a dividend.Dividend GrowthIntellia Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntellia Therapeutics has received a 74.63% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for genetic diseases", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Intellia Therapeutics is -0.67. Previous Next 2.6 News and Social Media Coverage News SentimentIntellia Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Intellia Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 32 people have searched for NTLA on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat Follows13 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 44% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intellia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $431,934.00 in company stock.Percentage Held by InsidersOnly 2.60% of the stock of Intellia Therapeutics is held by insiders.Percentage Held by Institutions85.61% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Intellia Therapeutics are expected to decrease in the coming year, from ($5.81) to ($5.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intellia Therapeutics is -6.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intellia Therapeutics is -6.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntellia Therapeutics has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Intellia Therapeutics (NASDAQ:NTLA) StockIntellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.Read More Receive NTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NTLA Stock News HeadlinesMarch 29, 2023 | americanbankingnews.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Forecasted to Post Q1 2023 Earnings of ($1.42) Per ShareMarch 28, 2023 | nasdaq.comGuru Fundamental Report for NTLA - Benjamin GrahamMarch 29, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 28, 2023 | 247wallst.comThese Are the Top 10 Holdings of Cathie WoodMarch 23, 2023 | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) Now Covered by Analysts at Sanford C. BernsteinMarch 21, 2023 | marketwatch.comIntellia Therapeutics Gets FDA RMAT Designation for NTLA-2002 in Hereditary AngioedemaMarch 17, 2023 | benzinga.comIntellia Therapeutics Stock (NASDAQ:NTLA), Short Interest ReportMarch 15, 2023 | msn.comBMO Capital Upgrades Intellia Therapeutics (NTLA)March 29, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 13, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Durect (DRRX) and Intellia Therapeutics (NTLA)March 8, 2023 | markets.businessinsider.com“Strong Buy” Intellia Therapeutics Stock (NASDAQ:NTLA) Still Requires PrudenceMarch 4, 2023 | nasdaq.comIntellia Therapeutics Climbs 7% On Clearance Of NDA For NTLA-2002March 3, 2023 | markets.businessinsider.comBMO Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA)March 2, 2023 | bloomberg.comIntellia Gets FDA Nod to Start Testing Crispr TherapyMarch 2, 2023 | markets.businessinsider.comWhy Is Intellia Therapeutics (NTLA) Stock Up 10% Today?March 2, 2023 | msn.comWhy Intellia Therapeutics Stock Jumped This WeekMarch 2, 2023 | msn.comIntellia stock rises on FDA nod to start trial of CRISPR gene editing therapyMarch 2, 2023 | reuters.comIntellia shares jump as gene therapy trial gets U.S. regulator nodMarch 2, 2023 | finance.yahoo.comIntellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene EditingFebruary 28, 2023 | msn.comIntellia Therapeutics Earnings Perspective: Return On Capital EmployedFebruary 26, 2023 | seekingalpha.comIntellia Therapeutics, Inc. (NTLA) Q4 2022 Earnings Call TranscriptFebruary 23, 2023 | msn.comIntellia Therapeutics GAAP EPS of -$1.40 misses by $0.04, revenue of $13.6M beats by $2.89MFebruary 23, 2023 | finance.yahoo.comIntellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company ProgressFebruary 22, 2023 | finance.yahoo.comIs Intellia Therapeutics (NTLA) Stock Outpacing Its Medical Peers This Year?February 22, 2023 | finance.yahoo.comBetter Buy: Beam Therapeutics or Intellia Therapeutics?February 16, 2023 | benzinga.com$14.2+ Billion Worldwide Gene Editing Industry to 2032 - Rising Infectious Diseases Drives GrowthFebruary 14, 2023 | benzinga.comIntellia Therapeutics Stock (NASDAQ:NTLA), Quotes and News SummarySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NTLA Company Calendar Last Earnings2/23/2023Today3/29/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTLA CUSIPN/A CIK1652130 Webwww.intelliatx.com Phone(857) 285-6200FaxN/AEmployees485Year FoundedN/APrice Target and Rating Average Stock Price Forecast$87.18 High Stock Price Forecast$180.00 Low Stock Price Forecast$39.00 Forecasted Upside/Downside+136.4%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)($6.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-474,190,000.00 Net Margins-909.78% Pretax Margin-909.78% Return on Equity-48.70% Return on Assets-38.57% Debt Debt-to-Equity RatioN/A Current Ratio9.61 Quick Ratio9.61 Sales & Book Value Annual Sales$52.12 million Price / Sales62.28 Cash FlowN/A Price / Cash FlowN/A Book Value$15.70 per share Price / Book2.35Miscellaneous Outstanding Shares88,020,000Free Float85,730,000Market Cap$3.25 billion OptionableOptionable Beta1.92 Key ExecutivesJohn M. LeonardPresident, Chief Executive Officer & DirectorGlenn GoddardChief Financial, Treasurer & Accounting OfficerLaura Sepp-LorenzinoChief Scientific Officer & Executive VPDavid LebwohlChief Medical Officer & Executive Vice PresidentEliana ClarkChief Technology Officer & Executive VPKey CompetitorsNeogenNASDAQ:NEOGMyriad GeneticsNASDAQ:MYGNCelldex TherapeuticsNASDAQ:CLDXLantheusNASDAQ:LNTHHeskaNASDAQ:HSKAView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCBought 3,930 shares on 3/23/2023Ownership: 0.050%Rockefeller Capital Management L.P.Sold 7,129 shares on 3/6/2023Ownership: 0.027%Voya Investment Management LLCBought 3,013 shares on 2/28/2023Ownership: 0.127%NatixisSold 349 shares on 2/24/2023Ownership: 0.005%Macquarie Group Ltd.Sold 479 shares on 2/21/2023Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions NTLA Stock - Frequently Asked Questions Should I buy or sell Intellia Therapeutics stock right now? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NTLA shares. View NTLA analyst ratings or view top-rated stocks. What is Intellia Therapeutics' stock price forecast for 2023? 18 equities research analysts have issued 1-year price objectives for Intellia Therapeutics' stock. Their NTLA share price forecasts range from $39.00 to $180.00. On average, they predict the company's stock price to reach $87.18 in the next year. This suggests a possible upside of 136.4% from the stock's current price. View analysts price targets for NTLA or view top-rated stocks among Wall Street analysts. How have NTLA shares performed in 2023? Intellia Therapeutics' stock was trading at $34.89 at the start of the year. Since then, NTLA stock has increased by 5.7% and is now trading at $36.88. View the best growth stocks for 2023 here. When is Intellia Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our NTLA earnings forecast. How were Intellia Therapeutics' earnings last quarter? Intellia Therapeutics, Inc. (NASDAQ:NTLA) released its quarterly earnings results on Thursday, February, 23rd. The company reported ($1.40) EPS for the quarter, hitting the consensus estimate of ($1.40). The business earned $13.60 million during the quarter, compared to the consensus estimate of $10.71 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 48.70% and a negative net margin of 909.78%. The firm's revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.09) earnings per share. What ETFs hold Intellia Therapeutics' stock? ETFs with the largest weight of Intellia Therapeutics (NASDAQ:NTLA) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion mRNA ETF (MSGR), ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), Direxion Moonshot Innovators ETF (MOON) and Franklin Genomic Advancements ETF (HELX). What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO? 12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees. What other stocks do shareholders of Intellia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO). When did Intellia Therapeutics IPO? (NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Intellia Therapeutics' stock symbol? Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA." Who are Intellia Therapeutics' major shareholders? Intellia Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (11.97%), Sumitomo Mitsui Trust Holdings Inc. (3.78%), Nikko Asset Management Americas Inc. (3.78%), Morgan Stanley (3.20%), Price T Rowe Associates Inc. MD (2.45%) and Alliancebernstein L.P. (2.15%). Insiders that own company stock include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Jose E Rivera, Laura Sepp-Lorenzino and Perry A Karsen. View institutional ownership trends. How do I buy shares of Intellia Therapeutics? Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Intellia Therapeutics' stock price today? One share of NTLA stock can currently be purchased for approximately $36.88. How much money does Intellia Therapeutics make? Intellia Therapeutics (NASDAQ:NTLA) has a market capitalization of $3.25 billion and generates $52.12 million in revenue each year. The company earns $-474,190,000.00 in net income (profit) each year or ($6.18) on an earnings per share basis. How many employees does Intellia Therapeutics have? The company employs 485 workers across the globe. How can I contact Intellia Therapeutics? Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The official website for the company is www.intelliatx.com. The company can be reached via phone at (857) 285-6200 or via email at lina.li@intelliatx.com. This page (NASDAQ:NTLA) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.